Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

AstraZeneca weighs seeking full U.S. approval for COVID-19 shot -WSJ

Fri, 7th May 2021 22:52

May 7 (Reuters) - AstraZeneca Plc may skip asking
the U.S. Food and Drug Administration for emergency-use
authorization for its COVID-19 vaccine, and instead pursue the
more time-intensive application for a full-fledged license to
sell the shot, the Wall Street Journal reported on Friday.

Such a step would further delay any rollout of the British
drugmaker's shots in the United States, according to the report, which cited people familiar with the
(Reporting by Kanishka Singh in Bengaluru
Editing by Chris Reese)

Related Shares

More News

AstraZeneca, MSD prostate cancer drug gets China green light

(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.

24 Jun 21 07:34

Wednesday broker round-up

(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.

23 Jun 21 13:04

Delta plus variant reclassified as 'variant of concern', experts sanguine for now

(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".

23 Jun 21 10:47

AstraZeneca's 'Orpathys' gets conditional approval in China

(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.

23 Jun 21 07:33

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.